We are joined today by biopharma expert Ivan Kairatov to discuss a groundbreaking development in the fight against a virus that over 80% of the global population carries, often without a clue: human cytomegalovirus, or HCMV. While dormant for most, this stealthy pathogen poses a life-threatening
In the high-stakes world of biopharmaceutical development, the line between a groundbreaking success and a costly failure is often defined by the unforgiving logic of statistical significance, a reality Nektar Therapeutics recently confronted with its autoimmune drug, rezpegaldesleukin. The company
For individuals born with the rare and debilitating genetic disorder Wiskott-Aldrich syndrome, the hope for a cure has long been shadowed by the immense challenge of finding a perfectly matched stem cell donor. This condition, which severely compromises the immune system and blood clotting, leaves
The intricate challenge of moving living, three-dimensional biological structures across countries and continents without compromising their integrity has long been a significant barrier to advancing global biomedical research. The development of non-cryogenic transport solutions represents a
The landscape of oncology funding is undergoing a profound and strategic transformation, moving decisively away from supporting purely theoretical research toward projects with a clear and direct path to real-world application. Grant-making organizations are now signaling a clear preference for
The journey to bring a new medicine to market is a monumental undertaking, frequently spanning over a decade and consuming more than two billion dollars in investment, a reality that has long created a significant bottleneck in addressing pressing global health challenges. In this high-stakes
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25